Goal 2: Reduce Human Disease

Development of right ventricular-targeted therapies in pulmonary arterial hypertension (PAH)

Pulmonary arterial hypertension (PAH) is a complex, progressive condition characterized by high blood pressure in the lungs and restriction of flow through the pulmonary arterial system. A great increase in the treatment armamentarium has been noted for this rare disease in the past 20 years, with 12 new PAH-targeted therapies. Though these therapies do improve cardiac performance, this is most likely due to their primary effect on the pulmonary arterial system and not by directly supporting the right ventricle (RV). The effect of PAH-targeted therapies and medications currently used in left heart disease on the adapting RV during PAH is not currently well characterized or known; novel therapies targeting the RV remain undiscovered.

Tags (Keywords associated with the idea)


66 net votes
75 up votes
9 down votes
Idea No. 794